



ViroGates announces financial guidance for 2024

21.12.2023 16:20:42 CET | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 24-2023 - Inside information - 21 December 2023

BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its financial guidance for 2024.

ViroGates expects full-year revenue between DKK 8 and 10 million in 2024 and an EBIT of DKK -10 to -12 million in 2024. Due to the uncertainty surrounding both sales to the acute care segment, underlined by adjustments made to the financial guidance for 2023 during the year, as well as the effects of ViroGates' recent entry into a new customer segment in longevity and general health management, ViroGates will pause its guidance to the market on becoming cash flow positive.

Jakob Knudsen, CEO of ViroGates, says: "We have had a difficult 2023 with respect to sales, and we did not perform to the extent we wanted. Unfortunately, this led to revisions to our financial guidance to the market during the year. We therefore believe we must postpone our guidance on cash flow positivity for the time being. We have continued belief in our products and value propositions and look forward to deliver based on our guidance for 2024. This goes for our new application areas, our entry into the longevity segment, and our continued close collaboration with Sobi on making suPARnostic® available in the US market".

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: ca@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff as well as to monitor health in the general population.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

- [20231221 - ViroGates comp. ann. 24.pdf](#)